A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Purdue Pharma LP
ClinicalTrials.gov Identifier:
NCT01427283
First received: August 30, 2011
Last updated: May 16, 2014
Last verified: May 2014
  Purpose

The primary objectives are to assess the analgesic efficacy of Oxycodone/Naloxone Controlled-release Tablets (OXN) compared to placebo and to assess the efficacy of OXN for the management of Opioid-induced Constipation (OIC) compared to Oxycodone Controlled-release Tablets (OXY) in subjects with moderate to severe pain due to chronic low back pain who require around-the-clock opioid therapy.


Condition Intervention Phase
Low Back Pain
Drug: Oxycodone/Naloxone controlled-release
Drug: Oxycodone HCl controlled-release
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation Who Require Around-the-clock Opioid Therapy

Resource links provided by NLM:


Further study details as provided by Purdue Pharma LP:

Primary Outcome Measures:
  • The "average pain over the last 24 hours" score at week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    The "average pain over the last 24 hours" score at week 12 of the double-blind period comparing OXN to placebo. The score is based on an 11-point numerical rating scale (NRS): 0 = no pain, 10 = pain as bad as you can imagine.

  • Overall complete spontaneous bowel movement (CSBM) responder rates [ Time Frame: Weeks 1 through 12 ] [ Designated as safety issue: No ]
    The overall Complete Spontaneous Bowel Movement (CSBM) responder rates over the 12 week double-blind period comparing OXN to OXY


Secondary Outcome Measures:
  • Sleep Disturbance Subscale of the Medical Outcomes Study (MOS) Sleep Scale [ Time Frame: Weeks 4, 8, and 12 ] [ Designated as safety issue: No ]
  • Patient Global Impression of Change (PGIC) [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • CSBM Responder at least 50% of the weeks in the double-blind period [ Time Frame: Weeks 1 through 12 ] [ Designated as safety issue: No ]
  • Laxative-free Responder at least 50% of the weeks in the double-blind period [ Time Frame: Weeks 1 through 12 ] [ Designated as safety issue: No ]

Estimated Enrollment: 900
Study Start Date: August 2011
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: OXN
Oxycodone/Naloxone controlled-release tablets (OXN)
Drug: Oxycodone/Naloxone controlled-release
Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
Active Comparator: OXY
Oxycodone HCl controlled-release tablets (OXY)
Drug: Oxycodone HCl controlled-release
Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
Other Name: OxyContin
Placebo Comparator: Placebo
Placebo tablets to match OXN or OXY
Drug: Placebo
Placebo tablets to match OXN or OXY taken orally every 12 hours

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria include:

  • Male and female subjects ≥ 18 years of age with moderate to severe, chronic low back pain (lasting at least several hours daily) as their predominant pain condition for at least 3 months prior to screening period;
  • The low back pain must be related to nonmalignant and nonneuropathic conditions and may be with or without radiation;
  • Subjects must have a self-reported history of opioid induced constipation (OIC).

Exclusion Criteria include:

  • Subjects with rheumatoid arthritis or other inflammatory arthritis;
  • Subjects with neuropathic conditions that have been painful or required therapy within the past 3 months;
  • Subjects with evidence of significant structural abnormalities of the gastrointestinal (GI) tract or other significant conditions affecting GI motility;
  • Subjects with chronic constipation not related to opioid use;
  • Subjects who had surgical procedures directed towards the source of chronic low back pain within 6 months of the screening visit or planned during the study;
  • Subjects with a history of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated.

Other protocol specific inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01427283

  Hide Study Locations
Locations
United States, Alabama
Investigational Site
Alabaster, Alabama, United States, 35007
Investigational Site
Birmingham, Alabama, United States, 35213
Investigational Site
Birmingham, Alabama, United States, 35216
Investigational Site
Foley, Alabama, United States, 36535
Investigational Site
Mobile, Alabama, United States, 36608
United States, Arizona
Investigational Site
Mesa, Arizona, United States, 85202
Investigational Site
Phoenix, Arizona, United States, 85021
Investigational Site
Phoenix, Arizona, United States, 85020
Investigational Site
Sun Lakes, Arizona, United States, 85248
Investigational Site
Tucson, Arizona, United States, 85712
Investigational Site
Tucson, Arizona, United States, 85704
United States, Arkansas
Investigational Site
Little Rock, Arkansas, United States, 72211
Investigational Site
Sherwood, Arkansas, United States, 72120
United States, California
Investigational Site
Anaheim, California, United States, 92801
Investigational Site
Anaheim, California, United States, 92804
Investigational Site
Artesia, California, United States, 90701
Investigational Site
Cerritos, California, United States, 90703
Investigational Site
Chino, California, United States, 91710
Investigational Site
El Cajon, California, United States, 92020
Investigational Site
Encino, California, United States, 91436
Investigational Site
Fountain Valley, California, United States, 92708
Investigational Site
Fresno, California, United States, 93720
Investigational Site
Garden Grove, California, United States, 92844
Investigational Site
Garden Grove, California, United States, 92843
Investigational Site
Laguna Hills, California, United States, 92653
Investigational Site
Lakewood, California, United States, 90712
Investigational Site
Lincoln, California, United States, 95648
Investigational Site
Lomita, California, United States, 90717
Investigational Site
Long Beach, California, United States, 90806
Investigational Site
Oceanside, California, United States, 92054
Investigational Site
Orange, California, United States, 92868
Investigational Site
Paramount, California, United States, 90723
Investigational Site
Sacramento, California, United States, 95823
Investigational Site
San Bernardino, California, United States, 92408
Investigational Site
San Diego, California, United States, 92114
Investigational Site
San Diego, California, United States, 92103
Investigational Site
Thousand Oaks, California, United States, 91360
Investigational Site
Torrance, California, United States, 90509
United States, Colorado
Investigational Site
Colorado Springs, Colorado, United States, 80909
Investigational Site
Colorado Springs, Colorado, United States, 80907
Investigational Site
Denver, Colorado, United States, 80246
Investigational Site
Golden, Colorado, United States, 80401
United States, Florida
Investigational Site
Aventura, Florida, United States, 33180
Investigational Site
Bradenton, Florida, United States, 34209
Investigational Site
Chiefland, Florida, United States, 32626
Investigational Site
Clermont, Florida, United States, 34711
Investigational Site
Daytona Beach, Florida, United States, 32117
Investigational Site
Deland, Florida, United States, 32720
Investigational Site
Edgewater, Florida, United States, 32132
Investigational Site
Ft. Lauderdale, Florida, United States, 33316
Investigational Site
Ft. Myers, Florida, United States, 33916
Investigational Site
Hialeah, Florida, United States, 33010
Investigational Site
Hialeah, Florida, United States, 33012
Investigational Site
Inverness, Florida, United States, 34452
Investigational Site
Jacksonville, Florida, United States, 32216
Investigational Site
Jacksonville, Florida, United States, 32257
Investigational Site
Jacksonville, Florida, United States, 32256
Investigational Site
Miami, Florida, United States, 33145
Investigational Site
Miami, Florida, United States, 33126
Investigational Site
Miami, Florida, United States, 33185
Investigational Site
Miami, Florida, United States, 33015
Investigational Site
Miami, Florida, United States, 33136
Investigational Site
Miami, Florida, United States, 33144
Investigational Site
Miami, Florida, United States, 33135
Investigational Site
Miami, Florida, United States, 33155
Investigational Site
Miami, Florida, United States, 33125
Investigational Site
Miami, Florida, United States, 33165
Investigational Site
Miami Beach, Florida, United States, 33140
Investigational Site
Naples, Florida, United States, 34110
Investigational Site
Naples, Florida, United States, 34113
Investigational Site
New Smyrna Beach, Florida, United States, 32168
Investigational Site
North Miami, Florida, United States, 33161
Investigational Site
Oldsmar, Florida, United States, 34677
Investigational Site
Orlando, Florida, United States, 32806
Investigational Site
Oviedo, Florida, United States, 32765
Investigational Site
Plantation, Florida, United States, 33317
Investigational Site
Tamarac, Florida, United States, 33321
Investigational Site
Tampa, Florida, United States, 33607
Investigational Site
West Palm Beach, Florida, United States, 33409
United States, Georgia
Investigational Site
Atlanta, Georgia, United States, 30308
Investigational Site
Austell, Georgia, United States, 30106
Investigational Site
Snellville, Georgia, United States, 30078
United States, Idaho
Investigational Site
Boise, Idaho, United States, 83713
Investigational Site
Boise, Idaho, United States, 83704
United States, Illinois
Investigational Site
Chicago, Illinois, United States, 60657
Investigational Site
Chicago, Illinois, United States, 60616
Investigational Site
Chicago, Illinois, United States, 60622
United States, Indiana
Investigational Site
Evansville, Indiana, United States, 47714
Investigational Site
Indianapolis, Indiana, United States, 46250
Investigational Site
Michigan City, Indiana, United States, 46360
United States, Kansas
Investigational Site
Wichita, Kansas, United States, 67203
United States, Kentucky
Investigational Site
Edgewood, Kentucky, United States, 41017
United States, Louisiana
Investigational Site
Lake Charles, Louisiana, United States, 70601
Investigational Site
Monroe, Louisiana, United States, 71201
Investigational Site
New Orleans, Louisiana, United States, 70119
United States, Maryland
Investigational Site
Pikesville, Maryland, United States, 21208
United States, Massachusetts
Investigational Site
Brockton, Massachusetts, United States, 02301
Investigational Site
Worcester, Massachusetts, United States, 01605
United States, Missouri
Investigational Site
Florissant, Missouri, United States, 63031
United States, Nevada
Investigational Site
Las Vegas, Nevada, United States, 89119
United States, New Jersey
Investigational Site
Atco, New Jersey, United States, 08004
United States, New York
Investigational Site
Great Neck, New York, United States, 11023
Investigational Site
Kew Gardens, New York, United States, 11415
Investigational Site
New York, New York, United States, 10023
Investigational Site
Rochester, New York, United States, 14618
Investigational Site
Williamsville, New York, United States, 14221
United States, North Carolina
Investigational Site
Durham, North Carolina, United States, 27710
Investigational Site
Elkin, North Carolina, United States, 28621
Investigational Site
High Point, North Carolina, United States, 27262
Investigational Site
Winston Salem, North Carolina, United States, 27103
Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Investigational Site
Columbus, Ohio, United States, 43213
Investigational Site
Dayton, Ohio, United States, 45406
Investigational Site
Moraine, Ohio, United States, 45439
Investigational Site
Toledo, Ohio, United States, 43614
United States, Oklahoma
Investigational Site
Oklahoma City, Oklahoma, United States, 73119
Investigational Site
Oklahoma City, Oklahoma, United States, 73103
Investigational Site
Oklahoma City, Oklahoma, United States, 73109
United States, Oregon
Investigational Site
Eugene, Oregon, United States, 97404
United States, Pennsylvania
Investigational Site
Jenkintown, Pennsylvania, United States, 19046
Investigational Site
Levittown, Pennsylvania, United States, 19056
Investigational Site
Mechanicsburg, Pennsylvania, United States, 17055
Investigational Site
Pittsburgh, Pennsylvania, United States, 15215
Investigational Site
Red Lion, Pennsylvania, United States, 17356
Investigational Site
State College, Pennsylvania, United States, 16801
United States, Rhode Island
Investigational Site
Warwick, Rhode Island, United States, 02886
United States, South Carolina
Investigational Site
Charleston, South Carolina, United States, 29406
Investigational Site
Myrtle Beach, South Carolina, United States, 29588
United States, South Dakota
Investigational Site
Rapid City, South Dakota, United States, 57702
United States, Tennessee
Investigational Site
Jackson, Tennessee, United States, 38305
United States, Texas
Investigational Site
Allen, Texas, United States, 75013
Investigational Site
Austin, Texas, United States, 78731
Investigational Site
Dallas, Texas, United States, 75218
Investigational Site
Dallas, Texas, United States, 75231
Investigational Site
Dallas, Texas, United States, 75203
Investigational Site
Dallas, Texas, United States, 75251
Investigational Site
Houston, Texas, United States, 77074
Investigational Site
Houston, Texas, United States, 77098
Investigational Site
Houston, Texas, United States, 77062
Investigational Site
Houston, Texas, United States, 77065
Investigational Site
McKinney, Texas, United States, 75070
Investigational Site
North Richland Hills, Texas, United States, 76180
Investigational Site
Tomball, Texas, United States, 77375
United States, Utah
Investigational Site
Orem, Utah, United States, 84058
Investigational Site
Salt Lake City, Utah, United States, 84102
Investigational Site
Salt Lake City, Utah, United States, 84124
United States, Virginia
Investigational Site
Danville, Virginia, United States, 24541
Investigational Site
Midlothian, Virginia, United States, 23114
Investigational Site
Richmond, Virginia, United States, 23220
United States, Washington
Investigational Site
Bothell, Washington, United States, 98011
Sponsors and Collaborators
Purdue Pharma LP
  More Information

No publications provided

Responsible Party: Purdue Pharma LP
ClinicalTrials.gov Identifier: NCT01427283     History of Changes
Other Study ID Numbers: ONU3705, 2011-005061-20
Study First Received: August 30, 2011
Last Updated: May 16, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Purdue Pharma LP:
Low back pain
Chronic pain
Opioid
Constipation
Moderate to severe

Additional relevant MeSH terms:
Back Pain
Constipation
Low Back Pain
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Signs and Symptoms, Digestive
Analgesics
Oxycodone
Naloxone
Analgesics, Opioid
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Narcotic Antagonists
Narcotics
Central Nervous System Depressants

ClinicalTrials.gov processed this record on July 22, 2014